Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Organon and Co
The study included a 12-week double-blind treatment phase and a 36-month open-label extension phase. Participants who completed or discontinued the initial 12-week phase of the study and who opted to participate in the open label extension phase were randomized to either losartan or enalapril at a dose of the investigator's choosing for the duration of the extension. The open label extension was designed to continue until the 100th participant completed 3 years of follow-up.
Age
1–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant is 1 to 17 years of age
Able to provide a first-morning urine sample each day during the study
Documented history of proteinuria associated with chronic kidney disease of any origin
Signed consent of parent and/or legal guardian
You may not be if
Pregnant and/or nursing
Requires more than 2 medications to control high blood pressure
Has undergone major organ transplantation (e.g. heart, kidney, liver)
Known sensitivity to losartan or other similar drugs, or any history of angioneurotic edema
Known sensitivity to amlodipine or other calcium channel blocker
Requires cyclosporine to treat renal disease (kidney disease)
Clareo Health | An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
